17th Mar 2026 11:00
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.
----------
AIM - WINNERS
----------
CRISM Therapeutics Corp, up 16% at 13.90 pence, 12-month range 29.40p-5.85p. The pharmaceutical company says the US Food & Drug Administration grants orphan drug designation to irinotecan for the treatment of malignant glioma. It says this is broader than the original designation request for glioblastoma, which is a grade four glioma, and includes all high grade gliomas. "The award of ODD represents an important regulatory and commercial milestone for CRISM and strengthens the development and value proposition of the irinotecan-ChemoSeed programme," the firm says. The designation is granted by the FDA to encourage the development of treatments for rare diseases. It provides incentives, including a potential seven years of US market exclusivity upon product approval, tax credits for clinical trials and an exemption from FDA application fees. "From a strategic perspective, this designation enhances the regulatory profile and potential commercial attractiveness of the programme and supports our strategy of advancing differentiated oncology assets that address significant unmet medical needs," says Chief Scientific Officer Chris McConville.
----------
Atlantic Lithium Ltd, up 14% at 16.17p, 12-month range 20.40p-5.32p. The lithium exploration company secures funding worth up to USD16.4 million. It says a group of Ghanaian pension funds subscribe for up to USD11.0 million, while a placement agreement with Long State Investments Ltd raises USD5.4 million. Atlantic Lithium says proceeds will be used to support the advancement of its flagship Ewoyaa lithium project in Ghana towards production. "The interest of the Ghanaian Investors in Atlantic Lithium reflects a broader desire in Ghana to see the country deliver upon its critical mineral promises and diversify its revenue stream beyond its existing portfolio, which is centred on gold," says Chief Executive Officer Keith Muller.
----------
AIM - LOSERS
----------
ImmuPharma PLC, down 21% at 5.50p, 12-month range 19.40p-1.39p. The specialist drug discovery and development company raises GBP6 million via a subscription with up to a further GBP1.5 million to be offered through a retail offering. The fundraising is at 6.0p per share. The net proceeds will be used to accelerate development of the Kapiglucagon programme in Type 1 diabetes. "Kapiglucagon is one of the earlier‑stage development programs, we have previously alluded to, as a potential high‑quality asset in our portfolio. Securing this funding, we expect it to deliver a strong stream of positive news flow over the next two years, as we advance it rapidly through its next stages of development," says Chief Executive Officer Tim McCarthy.
----------
Intercede Group PLC, down 18% at 79.99p, 12-month range 194.90p-76.01p. The cybersecurity software firm says it expects adjusted earnings before interest, tax, depreciation and amortisation to be around 15% and 18% below current market expectations for the financial year to the end of March. The current market consensus is for adjusted Ebitda of GBP4.6 million. Intercede says it expects to deliver annual recurring revenue growth, but sees full year revenue between 8% and 9% below current market expectations of GBP18.7 million. "This reflects procurement delays, particularly in the US, and customer purchasing deferrals attributable to heightened geopolitical uncertainty, including the ongoing Middle East conflict," the firm says. It notes that "these opportunities are delayed, not lost". Intercede reaffirms its financial 2027 revenue target of GBP21 million, which its says reflects its "confidence that the FY26 revenue delays represent timing shifts rather than fundamental demand weakness". "First, these are delays, not losses, as mentioned above. Our pipeline remains robust, customer engagements continue actively, and we are confident these opportunities will convert, especially should geopolitical conditions stabilise," says Chief Executive Officer Klaas van der Leest.
----------
By Michael Hennessey, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Crism TheraAtlantic LithiumIntercedeImmupharma